Publisher
Springer International Publishing
Reference56 articles.
1. Krings G, Bean GR, Chen Y-Y. Fibroepithelial lesions: the WHO spectrum. Semin Diagn Pathol. 2017;34(5):438–52. https://doi.org/10.1053/j.semdp.2017.05.006 .
2. Silverman JS, Tamsen A. Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages. Histopathology. 1996;29:411–9.
3. Kleer CG, Giordano TJ, Braun T, Oberman HA. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. Mod Pathol. 2001;14:185–90.
4. Sawyer EJ, Poulsom R, Hunt FT, Jeffery R, Elia G, Ellis IO, Ellis P, Tomlinson IPM, Hanby AM. Malignant phyllodes tumours show stromal expression of c-myc and c-kit. J Athol. 2003;200:59–64.
5. Borhani-Khomani K, Moller Talman M-L, Kroman N, Tvedskov TF. Risk of local recurrence of benign and borderline phyllodes tumors: a Danish population-based retrospective study. Ann Surg Oncol. 2016;23:1543–8.